Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Efficacy Study of Single-Dose Levalbuterol Tartrate HFA MDI Vs Placebo in Subjects 18 Years and Older With EIB

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00268723
Recruitment Status : Completed
First Posted : December 22, 2005
Last Update Posted : February 22, 2012
Information provided by (Responsible Party):

Brief Summary:
To determine if administration of levalbuterol tartrate HFA MDI in subjects with EIB will be effective in the prevention of EIB and be safe and well-tolerated.

Condition or disease Intervention/treatment Phase
Exercise-induced Bronchospasm Drug: Levalbuterol tartrate HFA MDI Drug: Placebo Phase 3

Detailed Description:
This was a randomized, double-blind, placebo-controlled, multicenter, two-way crossover study of levalbuterol tartrate HFA MDI in subjects 18 years of age and older with EIB. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: An Efficacy Study of Single-Dose Levalbuterol Tartrate HFA MDI Versus Placebo in Prevention of EIB in Subjects 18 Years of Age and Older With EIB
Study Start Date : December 2005
Actual Primary Completion Date : February 2006
Actual Study Completion Date : February 2006

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1
levalbuterol HFA MDI 90 mcg QID
Drug: Levalbuterol tartrate HFA MDI
levalbuterol MDI 90 mcg QID
Other Name: Xopenex MDI

Placebo Comparator: 2
Placebo MDI QID
Drug: Placebo
Placebo MDI QID

Primary Outcome Measures :
  1. maximum percent FEV1 decrease from visit postdose/prechallenge [ Time Frame: Days 1, 4, 7 ]

Secondary Outcome Measures :
  1. FEV1 area under the curve (AUC0-60 mins) (% decrease from visit postdose/prechallenge) [ Time Frame: Days 1, 4, 7 ]
  2. time to FEV1 recovery [ Time Frame: Days 1, 4, 7 ]
  3. minimum percent change in FEV1 from visit postdose/prechallenge [ Time Frame: Days 1, 4, 7 ]
  4. minimum percent change in FEV1 from visit predose [ Time Frame: Days 1, 4, 7 ]
  5. protected/unprotected subject counts (unprotected: >20% decrease; moderately protected: 10% to 20% decrease; and protected: <10% decrease from postdose/prechallenge FEV1) [ Time Frame: Days 1, 4, 7 ]
  6. percent change in FEV1 from predose to postdose/prechallenge [ Time Frame: Days 1, 4, 7 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Subjects were males or females and 18 years of age or older at the time of consent.
  • Female subjects considered not of childbearing potential were either surgically sterile or greater than one-year postmenopausal, defined as a complete cessation of menstruation for at least one year.
  • Female subjects of child-bearing potential had a negative urine pregnancy test at screening.
  • Female subjects of child-bearing potential agreed to use an acceptable method of birth control throughout the study.
  • Subjects were in good health and were not suffering from any chronic condition that might affect their respiratory or cardiac function (including cardiac arrhythmias).
  • Subjects had a documented diagnosis of exercise-induced bronchospasm for a minimum of 6 months prior to study start.
  • Subjects had stable baseline asthma and had been using a beta2-adrenergic agonist, and/or anti-asthma anti-inflammatory medication, and/or over-the-counter asthma medication for at least 6 months prior to study start.

Exclusion Criteria

  • Subjects with currently diagnosed life-threatening asthma defined as a history of: asthma episodes requiring intubation, associated hypercapnia, respiratory arrest, or hypoxic seizures within 12 months prior to study start.
  • Subjects with a history of hospitalization for asthma within 4 weeks prior to study start, or who were scheduled for in-patient hospitalization, including elective surgery, during the course of the trial.
  • Subjects with a documented history of bronchopulmonary aspergillosis or any form of allergic alveolitis.
  • Subjects who suffered from a clinically significant upper or lower respiratory tract infection in the 3 weeks prior to study start.
  • Subjects with any clinically significant unstable medical abnormality, chronic disease (other than asthma), or history of a clinically significant abnormality of the cardiovascular, gastrointestinal, respiratory, hepatic, renal, endocrine, or central nervous systems that was not currently well controlled by medication or that may have interfered with the successful completion of the protocol.
  • Subjects with a history of cancer (exception: basal-cell carcinoma in remission for a minimum of 5 years).
  • Subjects with a known sensitivity to levalbuterol, racemic albuterol, or any of the excipients contained in any of these formulations.
  • Subjects using any prescription drug with which levalbuterol tartrate administration is contraindicated.
  • Subjects with a history of substance abuse or drug abuse within 12 months preceding study start.
  • Subjects who participated in an investigational drug study within 30 days prior to study start, or who were currently participating in another clinical trial.
  • Subjects with a greater than 10-pack-year history of cigarette smoking or use of any tobacco products within 6 months of study start.
  • Subject was a staff member or relative of a staff member.
  • Subjects with unstable asthma, or had a change in asthma therapy, or a visit to the emergency department or hospital for worsening asthma within 4 weeks of study start.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00268723

Layout table for location information
United States, Colorado
Denver, Colorado, United States
United States, Virginia
Burke, Virginia, United States
Sponsors and Collaborators
Layout table for additonal information
Responsible Party: Sunovion Identifier: NCT00268723    
Other Study ID Numbers: 051-925
First Posted: December 22, 2005    Key Record Dates
Last Update Posted: February 22, 2012
Last Verified: February 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Bronchial Spasm
Asthma, Exercise-Induced
Bronchial Diseases
Respiratory Tract Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Tocolytic Agents
Reproductive Control Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action